Imaging Pulmonary Aspergillosis Using Gallium-68-Deferoxamine PETCT to Detect Lung Fungal Infections

What this Trial Is About

Researchers are evaluating the use of gallium-68-deferoxamine 68GaGa-DFO-B PETCT imaging to detect pulmonary Aspergillus infections, including chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. These fungal infections are increasing and can be difficult to diagnose with standard invasive tests. This phase 2 trial aims to show the feasibility of this non-invasive imaging method to visualize infections and distinguish them from cancer. Participants will receive a single intravenous injection of a fixed dose of 100 MBq 10% of 68GaGa-DFO-B, containing 100 micrograms of deferoxamine DFO-B. A PETCT scan will be performed 60 minutes after the injection to observe how the radiopharmaceutical accumulates at the infection site. This single-center, open-label trial involves a single study visit. During the visit, participants undergo the PETCT scan and researchers measure standardized uptake values and target-to-background ratios of the radiopharmaceutical to evaluate infection visualization. Participants must be able to lie still during the scan. The total participation involves just this one visit, and the study monitors how well this imaging technique works for diagnosing pulmonary aspergillosis.

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine